San Diego: Syngene International Limited announced its new launch Protein production platformplatform, using a cell line And Transposon-based technology Licensed from Swiss Biotech Services Company ExcelgeneIn collaboration with Syngene Clone Selection and promises significant improvements in efficiency and precision in development processes.

The new platform accelerates advanced protein production, allowing for faster preclinical and clinical development as well as product launches, reducing the time to bring a product to market.

“By combining Exelgene’s cell line and transposon-based platform with our proprietary processes, we are pushing the boundaries in cell line development. This innovative approach will not only accelerate development timelines, but also enhance the overall reliability and efficiency of the process, providing substantial benefits to our customers,” said Sridevi Khambhampati, vice president, Biopharmaceutical Development, Syngene International.

“Syngene sees biologics as a key driver for future growth, and we are committed to investing in cutting-edge technology to achieve reliability, precision and speed for customers. By combining Syngene’s skills and experience with Excelgene’s best-in-class cell line development technology, we can accelerate the process of bringing molecules to market for the people and patients who need them,” said Alex Del Priore, senior vice president, Syngene. Manufacturing ServicesSyngene International.

“High-yield manufacturing is a multifaceted exercise that begins with transfection and an optimized cell host. We are clearly delighted to partner and contribute to Syngene’s process development and manufacturing capabilities. This will leverage our technology and our cells (CHOExpress) for the benefit of their broad customer base. At Excelgene, we pride ourselves on spending decades studying the profound challenges in DNA transfer in cultured cells and linking the insights gained from such studies to their phenotype and use in manufacturing. We are delighted that our work, combined with the talent and expertise of the Syngene team, will directly benefit patients around the world,” said Maria J. and Florian M. Wurm, co-founders and managers of Excelgene.

The new platform simplifies clone selection and enhances operational productivity. It also supports a wide range of biomolecules, including monoclonal antibodies, biosimilars, bispecifics, antibody-drug conjugates, and other recombinant proteins. This versatility facilitates integration with both perfusion and fed-batch manufacturing processes. The track record of developing numerous monoclonal antibodies with the new technology underscores its effectiveness and reinforces Syngene’s ability to provide innovative solutions for its customers. By combining this technology with Syngene’s existing capabilities, the company now offers a full range of end-to-end cell line development options using the latest technology to deliver tangible benefits to customers.